{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:39:32Z","timestamp":1792089572962,"version":"4.4.0"},"reference-count":118,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders influenced by microbial, environmental, genetic, and immune factors. The introduction of biological agents has transformed IBD therapy, improving symptoms, reducing complications, and enhancing patients\u2019 quality of life. However, approximately 30% of patients exhibit primary non-response, and 50% experience a loss of response over time. Genetic and non-genetic factors contribute to variability in treatment outcomes. This systematic review aims to thoroughly analyze and assess existing studies exploring the relationships between genetic variations and individual responses to biologic drugs, in order to identify genetic markers that are predictive of treatment efficacy, risk of adverse effects, or drug toxicity, thereby informing clinical practice and guiding future research. PubMed and EMBASE papers were reviewed by three independent reviewers according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] guidelines. Of the 883 records screened, 99 met the inclusion criteria. The findings of this review represent an initial step toward personalized medicine in IBD, with the potential to improve clinical outcomes in biological therapy.<\/jats:p>","DOI":"10.3390\/ijms26041760","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:34:26Z","timestamp":1739943266000},"page":"1760","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5836","authenticated-orcid":false,"given":"Octavio","family":"Ballesta-L\u00f3pez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7398-8350","authenticated-orcid":false,"given":"Mayte","family":"Gil-Candel","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-6178","authenticated-orcid":false,"given":"Mar\u00eda","family":"Centelles-Oria","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Hematology, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6038-8151","authenticated-orcid":false,"given":"Hugo","family":"Ribes-Artero","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-1511","authenticated-orcid":false,"given":"Pilar","family":"Nos-Mateu","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Pellicer","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-6198","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Poveda-Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Accredited Research Group on Pharmacy, Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"},{"name":"Management Department, Hospital Universitari i Polit\u00e8cnic La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and Risk Factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12967-019-02174-1","article-title":"Integrating Omics for a Better Understanding of Inflammatory Bowel Disease: A Step towards Personalized Medicine","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_3","first-page":"CD000067","article-title":"Azathioprine or 6-Mercaptopurine for Maintenance of Remission in Crohn\u2019s Disease","volume":"10","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_5","first-page":"CD000543","article-title":"Oral 5-Aminosalicylic Acid for Induction of Remission in Ulcerative Colitis","volume":"4","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"I114","DOI":"10.1136\/ard.58.2008.i114","article-title":"Anti-TNF Antibody Treatment of Crohn\u2019s Disease","volume":"58","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Elhag, D.A., Kumar, M., Saadaoui, M., Akobeng, A.K., Al-Mudahka, F., Elawad, M., and Al Khodor, S. (2022). Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136966"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The Role of Early Biologic Therapy in Inflammatory Bowel Disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of Response and Need for Adalimumab Dose Intensification in Crohn\u2019s Disease: A Systematic Review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Anti-TNF Therapy in Crohn\u2019s Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082244"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting Durable Response or Resistance to Antitumor Necrosis Factor Therapy in Inflammatory Bowel Disease","volume":"9","author":"Kopylov","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent Advances in the Treatment of IBD: Targets, Mechanisms and Related Therapies","volume":"71\u201372","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Deyhim, T., Cheifetz, A.S., and Papamichael, K. (2023). Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227132"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00535-006-1995-7","article-title":"Inflammatory Bowel Disease: Past, Present, and Future","volume":"42","author":"Sands","year":"2007","journal-title":"J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2018.1494573","article-title":"How to Predict Response to Anti-Tumour Necrosis Factor Agents in Inflammatory Bowel Disease","volume":"12","author":"Naviglio","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/pgs.14.172","article-title":"Genetic Polymorphism in ATG16L1 Gene Influences the Response to Adalimumab in Crohn\u2019s Disease Patients","volume":"16","author":"Koder","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/tpj.2014.19","article-title":"Associations between Functional Polymorphisms in the NFKB Signaling Pathway and Response to Anti-TNF Treatment in Danish Patients with Inflammatory Bowel Disease","volume":"14","author":"Bank","year":"2014","journal-title":"Pharmacogenom. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPG.0000000000002840","article-title":"Genetic Predictors of Long-Term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease","volume":"71","author":"Bossacoma","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/apt.15187","article-title":"Polymorphisms in the NFkB, TNF-Alpha, IL-1beta, and IL-18 Pathways Are Associated with Response to Anti-TNF Therapy in Danish Patients with Inflammatory Bowel Disease","volume":"49","author":"Bank","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humimm.2013.09.017","article-title":"Role of TNFRSF1B Polymorphisms in the Response of Crohn\u2019s Disease Patients to Infliximab","volume":"75","author":"Medrano","year":"2014","journal-title":"Hum. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/apt.12010","article-title":"Genetic Polymorphisms of Tumour Necrosis Factor Receptor Superfamily 1b and Fas Ligand Are Associated with Clinical Efficacy and\/or Acute Severe Infusion Reactions to Infliximab in Crohn\u2019s Disease","volume":"36","author":"Steenholdt","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ibd.21174","article-title":"Genome Wide Association (GWA) Predictors of Anti-TNFalpha Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease","volume":"16","author":"Dubinsky","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/gastro\/goaa070","article-title":"Multi-Alleles Predict Primary Non-Response to Infliximab Therapy in Crohn\u2019s Disease","volume":"9","author":"Zhang","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jezernik, G., Gorenjak, M., and Potocnik, U. (2023). MIF Variant Rs755622 Is Associated with Severe Crohn\u2019s Disease and Better Response to Anti-TNF Adalimumab Therapy. Genes, 14.","DOI":"10.3390\/genes14020452"},{"key":"ref_26","first-page":"16461","article-title":"Association of the ILR1 and FAS Genes Variants with a Primary Non-Response to Anti-TNF Therapy in Crohn\u2019s Disease Patients","volume":"133","author":"Zuraszek","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Walczak, M., Lykowska-Szuber, L., Plucinska, M., Stawczyk-Eder, K., Zakerska-Banaszak, O., Eder, P., Krela-Kazmierczak, I., Michalak, M., Zywicki, M., and Karlowski, W.M. (2020). Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated with a Primary Response to Anti-TNF Therapy in Crohn\u2019s Disease Patients?. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01207"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","article-title":"Polymorphisms in Apoptosis Genes Predict Response to Infliximab Therapy in Luminal and Fistulizing Crohn\u2019s Disease","volume":"22","author":"Hlavaty","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.3748\/wjg.v23.i27.4958","article-title":"Genetic Polymorphisms Predict Response to Anti-Tumor Necrosis Factor Treatment in Crohn\u2019s Disease","volume":"23","author":"Netz","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00228-012-1389-0","article-title":"Influence of Polymorphisms and TNF and IL1beta Serum Concentration on the Infliximab Response in Crohn\u2019s Disease and Ulcerative Colitis","volume":"69","author":"Pedrero","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/ajg.2016.408","article-title":"Genetic Markers Predict Primary Non-Response and Durable Response to Anti-TNF Biologic Therapies in Crohn\u2019s Disease","volume":"111","author":"Barber","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","first-page":"11","article-title":"Pharmacogenetics of Anti-TNF Therapy in Paediatric Crohns\u2019 Disease and Ulcerative Colitis. Comparison with Adults","volume":"68","author":"Bossacoma","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ibd\/izy083","article-title":"Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis","volume":"24","author":"Burke","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104478","DOI":"10.1016\/j.phrs.2019.104478","article-title":"Genetic Predictors of Long-Term Response and Trough Levels of Infliximab in Crohn\u2019s Disease","volume":"149","author":"Lobato","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"106859","DOI":"10.1016\/j.phrs.2023.106859","article-title":"Polymorphisms Indicating Risk of Inflammatory Bowel Disease or Antigenicity to Anti-TNF Drugs as Biomarkers of Response in Children","volume":"194","author":"Velasco","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/gastro\/goz056","article-title":"Association of Polymorphisms in C1orf106, IL1RN, and IL10 with Post-Induction Infliximab Trough Level in Crohn\u2019s Disease Patients","volume":"8","author":"Tang","year":"2020","journal-title":"Gastroenterol. Rep. Oxf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/1751-2980.12677","article-title":"Mutations in the NOD2 Gene Are Associated with a Specific Phenotype and Lower Anti-Tumor Necrosis Factor Trough Levels in Crohn\u2019s Disease","volume":"19","author":"Geiss","year":"2018","journal-title":"J. Dig. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/cts.13075","article-title":"Pharmacogenetic Variants of Infliximab Response in Young Patients with Inflammatory Bowel Disease","volume":"14","author":"Curci","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhu, K., Ding, X., Chen, Z., Xi, Q., Pang, X., Chen, W., and Miao, L. (2023). Association between Genetic Variants and Development of Antibodies to Infliximab: A Cross-Sectional Study in Chinese Patients with Crohn\u2019s Disease. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1096816"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7150\/ijms.22812","article-title":"A FCGR3A Polymorphism Predicts Anti-Drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated with Anti-TNF","volume":"15","author":"Pedregosa","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hu, W., Feng, Y., Ye, Z., Tang, Z., Qian, L., Wang, Y., and Huang, Y. (2021). The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients with Crohn\u2019s Disease in China. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.744599"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S-72","DOI":"10.1016\/S0016-5085(21)00918-5","article-title":"Hispanic IBD patients with HLA-DQA1*05 have higher rates of anti-TNF immunogenicity compared to non-carriers","volume":"160","author":"Ioannou","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn\u2019s Disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Spencer, E.A., Dubinsky, M.C., Kamm, M.A., Chaparro, M., Gionchetti, P., Rizzello, F., Gisbert, J.P., Wright, E.K., Schulberg, J.D., and Hamilton, A.L. (2024). Poor Prognostic Factors of Pharmacokinetic Origin Predict Outcomes in Inflammatory Bowel Disease Patients Treated with Anti-Tumor Necrosis Factor-\u03b1. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1342477"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 Genotype Predicts Anti-Drug Antibody Formation and Loss of Response during Infliximab Therapy for Inflammatory Bowel Disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41397-023-00304-z","article-title":"One Year of Experience with Combined Pharmacokinetic\/Pharmacogenetic Monitoring of Anti-TNF Alpha Agents: A Retrospective Study","volume":"23","author":"Cheli","year":"2023","journal-title":"Pharmacogenom. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Laserna-Mendieta, E.J., Salvador-Mart\u00edn, S., Arias, A., L\u00f3pez-Cauce, B., Mar\u00edn-Jim\u00e9nez, I., Mench\u00e9n, L.A., Mar\u00edn-Rubio, L., Onta\u00f1\u00e1n Rodr\u00edguez, J., L\u00f3pez-Fern\u00e1ndez, L.A., and Lucendo, A.J. (2023). Single Nucleotide Polymorphisms in ADAM17, IL23R and SLCO1C1 Genes Protect against Infliximab Failure in Adults with Crohn\u2019s Disease. Biomed. Pharmacother., 159.","DOI":"10.1016\/j.biopha.2023.114225"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/MIB.0000000000001150","article-title":"Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD","volume":"23","author":"Yoon","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12967-017-1355-9","article-title":"Genetic Polymorphism in ATG16L1 Gene Is Associated with Adalimumab Use in Inflammatory Bowel Disease","volume":"15","author":"Nuij","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/omi.2016.0005","article-title":"A Prospective Pharmacogenomic Study of Crohn\u2019s Disease Patients during Routine Therapy with Anti-TNF Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability","volume":"20","author":"Dezelak","year":"2016","journal-title":"OMICS J. Integr. Biol."},{"key":"ref_51","first-page":"1670","article-title":"Missense Variant Rs3740691 in Gene ARFGAP2 Predicts Short-Term Nonresponse to Anti-TNF Inhibitor Adalimumab in Crohn\u2019s Disease Patients","volume":"27","author":"Repnik","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/S0016-5085(17)31514-7","article-title":"UBE2L3, ANCA, ASCA, and CBIR1 Are Associated with Mechanisms of Non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels","volume":"152","author":"Zhu","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41397-019-0090-4","article-title":"Genetic Association between CD96 Locus and Immunogenicity to Anti-TNF Therapy in Crohn\u2019s Disease","volume":"19","author":"Aterido","year":"2019","journal-title":"Pharmacogenom. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.14309\/01.ajg.0000777364.76967.26","article-title":"Pharmacogene CYP1A2*1F Polymorphism Lowers Anti-Tnf (Infliximab) Response in Inflammatory Bowel Disease Patients","volume":"116","author":"Wang","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Gorenjak, M., Zupin, M., Jezernik, G., Skok, P., and Potocnik, U. (2021). Omics Data Integration Identifies ELOVL7 and MMD Gene Regions as Novel Loci for Adalimumab Response in Patients with Crohn\u2019s Disease. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84909-z"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between Polymorphism in IgG Fc Receptor IIIa Coding Gene and Biological Response to Infliximab in Crohn\u2019s Disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc Receptor Gene FCGR3A and Response to Infliximab in Crohn\u2019s Disease: A Subanalysis of the ACCENT I Study","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00251-013-0679-8","article-title":"FCGR3A-158 Polymorphism Influences the Biological Response to Infliximab in Crohn\u2019s Disease through Affecting the ADCC Activity","volume":"65","author":"Moroi","year":"2013","journal-title":"Immunogenetics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-014-0225-3","article-title":"Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn\u2019s Disease","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","first-page":"535","article-title":"Association between Tumor Necrosis Factor-Alpha and Fc-Gamma Receptor Polymorphisms with Infliximab in Crohn\u2019s Disease","volume":"57","author":"Tomita","year":"2010","journal-title":"Hepatogastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Salvador-Mart\u00edn, S., Kaczmarczyk, B., \u00c1lvarez, R., Navas-L\u00f3pez, V.M., Gallego-Fern\u00e1ndez, C., Moreno-\u00c1lvarez, A., Solar-Boga, A., S\u00e1nchez, C., Tolin, M., and Velasco, M. (2021). Whole Transcription Profile of Responders to Anti-Tnf Drugs in Pediatric Inflammatory Bowel Disease. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010077"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/ajg.2016.306","article-title":"A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease","volume":"111","author":"Billiet","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ibd\/izac188","article-title":"Decreased Infliximab Concentrations in Patients with Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype","volume":"29","author":"Choi","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"318207","DOI":"10.1155\/2015\/318207","article-title":"Response to Infliximab in Crohn\u2019s Disease: Genetic Analysis Supporting Expression Profile","volume":"2015","author":"Medrano","year":"2015","journal-title":"Mediators Inflamm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/jgh.14652","article-title":"ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases","volume":"34","author":"Jung","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10528-016-9734-0","article-title":"Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn\u2019s Disease Patients","volume":"54","author":"Repnik","year":"2016","journal-title":"Biochem. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1093\/ecco-jcc\/jjz203.839","article-title":"P711 Carriage of the HLA-DQA1*05 Allele Is Associated with a High Risk of Loss of Response to Adalimumab in Patients with Crohn\u2019s Disease","volume":"14","author":"Serra","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1093\/ecco-jcc\/jjab076.390","article-title":"P264 Impact of the HLA-DQ1*05 Alelle on the Initial Response to Infliximab in Patients with Inflammatory Bowel Disease","volume":"15","author":"Marin","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ibd\/izac259","article-title":"Influence of HLADQA1*05 Genotype in Adults with Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study","volume":"29","author":"Garrote","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Salvador-Mart\u00edn, S., Zapata-Cobo, P., Velasco, M., Palomino, L.M., Clemente, S., Segarra, O., S\u00e1nchez, C., Tol\u00edn, M., Moreno-\u00c1lvarez, A., and Fern\u00e1ndez-Lorenzo, A. (2023). Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021797"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S-801","DOI":"10.1016\/S0016-5085(22)61892-4","article-title":"A serogenetic panel combining poor prognostic factors of pharmacokinetic and pharmacogenetic origin impacts time to remission during infliximab therapy in inflammatory bowel diseases","volume":"162","author":"Spencer","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3748\/wjg.v11.i8.1187","article-title":"IBD5 Polymorphisms in Inflammatory Bowel Disease: Association with Response to Infliximab","volume":"11","author":"Urcelay","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/tpj.2016.84","article-title":"Genetically Determined High Activity of IL-12 and IL-18 in Ulcerative Colitis and TLR5 in Crohns Disease Were Associated with Non-Response to Anti-TNF Therapy","volume":"18","author":"Bank","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_74","first-page":"680","article-title":"Cross Disease Pharmacogenetic Analysis Predicting Anti-TNF Response Identifies SNPs Predicting Adalimumab Response in Crohn\u2019s Disease Patients","volume":"26","author":"Repnik","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Urabe, S., Isomoto, H., Ishida, T., Maeda, K., Inamine, T., Kondo, S., Higuchi, N., Sato, K., Uehara, R., and Yajima, H. (2015). Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn\u2019s Disease. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/416838"},{"key":"ref_76","first-page":"S479","article-title":"Impact of the Rs1143634 Polymorphism in the Gene Coding for IL1beta on Pharmacokinetic of Infliximab in Inflammatory Bowel Disease Patients","volume":"10","author":"Guardiola","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_77","first-page":"A182","article-title":"Impact of the RS1143634 Polymorphism of Interleukin 1b on Infliximab Exposure in Crohn\u2019s Disease and Ulcerative Colitis Patients","volume":"23","author":"Santacana","year":"2016","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ecco-jcc\/jjz017","article-title":"Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients with Inflammatory Bowel Disease","volume":"13","author":"Wang","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.mrfmmm.2006.09.002","article-title":"Analysis of Linkage between Lymphotoxin Alpha Haplotype and Polymorphisms in 5\u2019-Flanking Region of Tumor Necrosis Factor Alpha Gene Associated with Efficacy of Infliximab for Crohn\u2019s Disease Patients","volume":"602","author":"Ozeki","year":"2006","journal-title":"Mutat. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","article-title":"ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn\u2019s Disease","volume":"120","author":"Taylor","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_81","first-page":"S19","article-title":"Prediction of Anti-TNF Response in Inflammatory Bowel Disease (IBD) Patients Using a Haplotype TAG-SNP (htSNP) Method","volume":"87","author":"Perera","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bcp.14400","article-title":"Pharmacogenetics of Trough Serum Anti-TNF Levels in Paediatric Inflammatory Bowel Disease","volume":"87","author":"Segarra","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-014-1020-5","article-title":"Anti-TNF-Alpha Loss of Response Is Associated with a Decreased Percentage of FoxP3+ T Cells and a Variant NOD2 Genotype in Patients with Crohn\u2019s Disease","volume":"50","author":"Juanola","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10620-011-1977-3","article-title":"NOD2 Polymorphism Predicts Response to Treatment in Crohn\u2019s Disease-First Steps to a Personalized Therapy","volume":"57","author":"Niess","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hoffmann, P., Lamerz, D., Hill, P., Kirchner, M., and Gauss, A. (2021). Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn\u2019s Disease: On the Way to Personalized Medicine?. Genes, 12.","DOI":"10.3390\/genes12060866"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000444479","article-title":"The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort","volume":"93","author":"Spalinger","year":"2016","journal-title":"Digestion"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/FPC.0000000000000471","article-title":"Pharmacogenetic Analysis of Canonical versus Noncanonical Pathway of NF-kB in Crohn\u2019s Disease Patients under Anti-Tumor Necrosis Factor-alfa Treatment","volume":"32","author":"Stavrou","year":"2022","journal-title":"Pharmacogenet. Genom."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Matsuoka, K., Hamada, S., Shimizu, M., Nanki, K., Mizuno, S., Kiyohara, H., Arai, M., Sugimoto, S., Iwao, Y., and Ogata, H. (2018). Factors Predicting the Therapeutic Response to Infliximab during Maintenance Therapy in Japanese Patients with Crohn\u2019s Disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204632"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/iji.12059","article-title":"Genetic Polymorphisms of Tumour Necrosis Factor Alpha (TNF-\u03b1) Promoter Gene and Response to TNF-\u03b1 Inhibitors in Spanish Patients with Inflammatory Bowel Disease","volume":"41","author":"Campillo","year":"2014","journal-title":"Int. J. Immunogenet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2036.2008.03630.x","article-title":"Genetic Polymorphisms of Tumour Necrosis Factor Receptor Superfamily 1A and 1B Affect Responses to Infliximab in Japanese Patients with Crohn\u2019s Disease","volume":"27","author":"Matsukura","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","article-title":"Tumour Necrosis Factor-Alpha Receptor 1 and 2 Polymorphisms in Inflammatory Bowel Disease and Their Association with Response to Infliximab","volume":"20","author":"Pierik","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_92","first-page":"733","article-title":"A Novel SNP in Tnfrsf1b Is Associated with Response to Anti-TNF Therapy in Inflammatory Bowel Disease Patients","volume":"62","author":"Smithberger","year":"2014","journal-title":"J. Investig. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/jgh3.12398","article-title":"TL1A (TNFSF15) Genotype Affects the Long-Term Therapeutic Outcomes of Anti-TNF Antibodies for Crohn\u2019s Disease Patients","volume":"4","author":"Endo","year":"2020","journal-title":"JGH Open"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jgh.14696","article-title":"Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn\u2019s Disease","volume":"34","author":"Park","year":"2019","journal-title":"J. Gastroenterol. Hepatol. Aust."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3748\/wjg.v20.i13.3609","article-title":"Association of Rs1568885, Rs1813443 and Rs4411591 Polymorphisms with Anti-TNF Medication Response in Greek Patients with Crohn\u2019s Disease","volume":"20","author":"Thomas","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5152\/tjg.2020.19436","article-title":"The Role of FAS Gene Variants in Inflammatory Bowel Disease","volume":"31","author":"Demir","year":"2020","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_97","first-page":"35","article-title":"Association of TNF and Fc\u03b3R\u0399\u0399\u0399A Gene Polymorphisms with Differential Response to Infliximab in a Greek Cohort of Crohn\u2019s Disease Patients","volume":"24","author":"Papamichael","year":"2011","journal-title":"Ann. Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1152\/physiol.00025.2014","article-title":"NOD-Like Receptors: Guardians of Intestinal Mucosal Barriers","volume":"30","author":"Claes","year":"2015","journal-title":"Physiology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12964-024-01533-w","article-title":"Role of the NF-kB Signalling Pathway in Heterotopic Ossification: Biological and Therapeutic Significance","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal. CCS"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/00365520601101559","article-title":"ATP-Binding Cassette Transporter ABCG2 (BCRP) and ABCB1 (MDR1) Variants Are Not Associated with Disease Susceptibility, Disease Phenotype Response to Medical Therapy or Need for Surgeryin Hungarian Patients with Inflammatory Bowel Diseases","volume":"42","author":"Fischer","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/01.fpc.0000230117.26581.a4","article-title":"The TNF\/ADAM 17 System: Implication of an ADAM 17 Haplotype in the Clinical Response to Infliximab in Crohn\u2019s Disease","volume":"16","author":"Dideberg","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/gtmb.2015.0036","article-title":"Association of Survivin Promoter Polymorphisms with Inflammatory Bowel Disease and Response to Antitumor Necrosis Factor Therapy","volume":"19","author":"Rapti","year":"2015","journal-title":"Genet Test Mol Biomark."},{"key":"ref_103","first-page":"591","article-title":"NOD2, CD14 and TLR4 Mutations Do Not Influence Response to Adalimumab in Patients with Crohn\u2019s Disease: A Preliminary Report","volume":"102","author":"Ouburg","year":"2010","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.fpc.0000182776.57437.d8","article-title":"No Association between C-Reactive Protein Gene Polymorphisms and Decrease of C-Reactive Protein Serum Concentration after Infliximab Treatment in Crohn\u2019s Disease","volume":"16","author":"Willot","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.14309\/01.ajg.0000776332.13982.cb","article-title":"Early Proactive Ifx Dose Optimization Negates the Impact of HLA-DQA1*05 on Anti-Drug Antibody Formation in Inflammatory Bowel Diseases","volume":"116","author":"Spencer","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.3748\/wjg.v18.i36.5058","article-title":"Crohn\u2019s Disease Genotypes of Patients in Remission vs Relapses after Infliximab Discontinuation","volume":"18","author":"Lu","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32832a06bf","article-title":"IgG1 Heavy Chain-Coding Gene Polymorphism (G1m Allotypes) and Development of Antibodies-to-Infliximab","volume":"19","author":"Vermeire","year":"2009","journal-title":"Pharmacogenet. Genom."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.fpc.0000204993.91806.b1","article-title":"Lymphotoxin Alpha Gene in Crohn\u2019s Disease Patients: Absence of Implication in the Response to Infliximab in a Large Cohort Study","volume":"16","author":"Dideberg","year":"2006","journal-title":"Pharmacogenet. Genom."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-2036.2005.02701.x","article-title":"Multidrug Resistance 1 Gene Polymorphisms Are Not Associated with Inflammatory Bowel Disease and Response to Therapy in Italian Patients","volume":"22","author":"Palmieri","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Nani, P., Ladopoulou, M., Papaioannou, E.H., Papagianni, E.D., Antonatos, C., Xiropotamos, P., Kapsoritakis, A., Potamianos, P.S., Karmiris, K., and Tzathas, C. (2023). Pharmacogenetic Analysis of the MIR146A Rs2910164 and MIR155 Rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn\u2019s Disease and Psoriasis. Genes, 14.","DOI":"10.3390\/genes14020445"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4292\/wjgpt.v8.i4.193","article-title":"Association of miR-146 Rs2910164, miR-196a Rs11614913, miR-221 Rs113054794 and miR-224 Rs188519172 Polymorphisms with Anti-TNF Treatment Response in a Greek Population with Crohn\u2019s Disease","volume":"8","author":"Papaconstantinou","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00008571-200210000-00002","article-title":"Response to Infliximab Treatment in Crohn\u2019s Disease Is Not Associated with Mutations in the CARD15 (NOD2) Gene: An Analysis in 534 Patients from Two Multicenter, Prospective GCP-Level Trials","volume":"12","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenetics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","article-title":"NOD2\/CARD15 Does Not Influence Response to Infliximab in Crohn\u2019s Disease","volume":"123","author":"Vermeire","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation before Treatment but Not with -308 TNF Gene Polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_115","first-page":"597","article-title":"Pharmacogenetics of Inflammatory Bowel Disease","volume":"18","author":"Mascheretti","year":"2004","journal-title":"Best Pr. Res. Clin. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Plaza, J., M\u00ednguez, A., Bastida, G., Marqu\u00e9s, R., Nos, P., Poveda, J.L., and Moret-Tatay, I. (2024). Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073717"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lauro, R., Mannino, F., Irrera, N., Squadrito, F., Altavilla, D., and Squadrito, G. (2021). Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121748"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Al-Sofi, R.F., Bergmann, M.S., Nielsen, C.H., Andersen, V., Skov, L., and Loft, N. (2024). The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115793"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1760\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:37:40Z","timestamp":1760027860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/4\/1760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":118,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26041760"],"URL":"https:\/\/doi.org\/10.3390\/ijms26041760","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}